GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (LTS:0K16) » Definitions » NonCurrent Deferred Liabilities

Evolus (LTS:0K16) NonCurrent Deferred Liabilities : $0.0 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Evolus NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Evolus's non-current deferred liabilities for the quarter that ended in Mar. 2025 was $0.0 Mil.

Evolus NonCurrent Deferred Liabilities Historical Data

The historical data trend for Evolus's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus NonCurrent Deferred Liabilities Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.04 0.02 0.03 0.01

Evolus Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.01 -

Evolus NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Evolus's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (LTS:0K16) » Definitions » NonCurrent Deferred Liabilities
Comparable Companies
NIKA ELTP ETON AKBA TLRY SIGA ZYBT ORGO AVDL EBS ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
EOLS:USA EVL:Germany
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Website
https://www.evolus.com
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines